Intracranial Subarachnoidal Route of Infection for Investigating Roles of Streptococcus suis Biofilms in Meningitis in a Mouse Infection Model
July 1st, 2018
6.6K views
Here, we describe the intracranial subarachnoidal route of infection in mice to study roles of biofilms in Streptococcus suis meningitis. This infection model is also suitable for studying the pathogenesis of other bacterial meningitis and the efficacy of new drugs against bacterial meningitis.
Overview
This study describes an intracranial subarachnoidal route of infection in mice to investigate the role of biofilms in Streptococcus suis meningitis. The model is also applicable for studying other bacterial meningitis pathogenesis and evaluating new drug efficacy.
Key Study Components
Area of Science
- Neuroscience
- Microbiology
- Infectious Diseases
Background
- Streptococcus suis is a significant pathogen causing meningitis.
- Biofilms play a crucial role in bacterial infections.
- Understanding the immune response in the brain is vital for developing treatments.
- This model mimics bacterial entry into the central nervous system.
Purpose of Study
- To investigate the roles of biofilms in bacterial meningitis.
- To evaluate the pathogenesis of Streptococcus suis.
- To assess the efficacy of new therapeutic drugs.
Methods Used
- Intracranial subarachnoidal infection model in mice.
- Collection of strain P1/7 planktonic cells from culture.
- Centrifugation and washing of cells in PBS.
- Re-suspension of cells in glycerol for storage.
Main Results
- The method allows for direct investigation of bacterial components affecting immune responses.
- Demonstrated the procedure effectively mimics bacterial entry into the CNS.
- Facilitated understanding of biofilm roles in meningitis.
- Provided a platform for testing new drugs against bacterial meningitis.
Conclusions
- The intracranial model is a valuable tool for studying bacterial meningitis.
- Insights gained can inform future therapeutic strategies.
- Further research is needed to explore other bacterial pathogens.
Frequently Asked Questions
What is the significance of biofilms in bacterial infections?
Biofilms protect bacteria from the immune system and antibiotics, making infections harder to treat.
How does this model mimic bacterial entry into the CNS?
The intracranial subarachnoidal route allows researchers to study the infection process directly in the brain environment.
What are the potential applications of this research?
This research can lead to better understanding and treatment of bacterial meningitis and other CNS infections.
Who conducted the study?
The study was conducted by Mister Shouming Zhang, a graduate student in the laboratory.
What are the next steps in this research?
Future studies will focus on testing new drugs and exploring other bacterial pathogens.
Can this model be used for other types of meningitis?
Yes, the model is suitable for studying the pathogenesis of various bacterial meningitis.
Executive Industry Relevance
The intracranial subarachnoidal infection model enables direct interrogation of Streptococcus suis biofilm contributions to meningitis pathogenesis within the central nervous system. This approach enhances predictive confidence in target validation by isolating bacterial components and their immune-modulatory effects in a disease-relevant system. The model supports translational continuity from mechanistic discovery to preclinical evaluation of anti-meningitis interventions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic de-risking by directly assessing biofilm-mediated immune activation in brain tissue.
- Clarifies the functional role of bacterial surface components in CNS infection models.
- Supports predictive confidence for target selection by quantifying host response to distinct bacterial states.
Screening & Assay Development
- Facilitates preparation of validated infection models for downstream compound screening.
- Enables reproducible measurement of cytokine and TLR2 mRNA expression as quantitative outputs.
- Supports standardization of infection dose and model parameters for cross-study comparability.
Translational & Preclinical Research
- Aligns with disease-relevant CNS infection models for translational biomarker assessment.
- Provides continuity from mechanistic studies to preclinical drug efficacy testing in meningitis.
- Enables risk-adjusted advancement decisions based on direct CNS immune response data.
Pipeline & Workflow Integration
This model positions within the discovery-to-preclinical continuum, bridging mechanistic studies of bacterial pathogenesis with preclinical evaluation of anti-meningitis agents.
- Discovery Biology: Supports hypothesis testing on biofilm-mediated immune modulation in the CNS.
- Screening: Provides a platform for quantitative assessment of infection severity and immune activation.
- Analytics: Delivers mRNA expression and histopathological readouts for comparative analysis.
- Translational Research: Connects mechanistic findings to preclinical validation in a disease-relevant mouse model.
- Enterprise Reuse: Offers a reusable infection model adaptable to other bacterial meningitis studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and reduces mechanistic ambiguity in CNS infection models.
- Operational Value: Standardizes infection procedures and quantitative outputs for reproducibility.
- Strategic Value: Informs go/no-go decisions for anti-meningitis candidates and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of CNS infection targets and interventions.
Implementation Considerations
- Requires expertise in CNS infection models and intracranial injection techniques.
- Needs access to quantitative PCR, histopathology, and animal handling infrastructure.
- Demands cross-team standardization of infection dose and readout protocols.
- Adaptable to different bacterial strains with preliminary dose-finding experiments.
- Model limitations include strain-specific infectivity and technical complexity of CNS delivery.
Biopharma FAQs
Why does null hypothesis testing matter for biofilm-induced cytokine analysis?
Null hypothesis testing ensures that observed increases in cytokine mRNA expression following biofilm infection are statistically significant and not due to random variation, supporting robust target validation in CNS infection models.
How does independent variable isolation apply to planktonic versus biofilm infection?
By directly comparing planktonic and biofilm state cell infections, the model isolates the effect of bacterial growth state as the independent variable, clarifying its specific impact on host immune response in the brain.
What do quantitative mRNA measurements enable in this infection model?
Quantitative mRNA measurements of TLR2 and cytokines provide objective, reproducible readouts for comparing immune activation across experimental groups, enabling data-driven assessment of infection severity and intervention efficacy.
Why are replication requirements critical for cross-functional CNS infection studies?
Replication ensures that findings on biofilm-induced pathology and immune response are consistent and reproducible, facilitating reliable data sharing and decision-making across discovery, screening, and translational teams.
What statistical analysis capabilities are needed before implementing mRNA expression readouts?
Robust statistical analysis, such as the two minus delta delta CT method for qPCR data, is required to validate differential gene expression and support confident interpretation of CNS infection outcomes in preclinical research.
